Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis causes progressive morbidity and has a worldwide incidence that is increasing. There are a number of promising therapies, one of which has been approved in Europe, parts of Asia, and India, and others that are at various stages of development. Despite this, there continues to be debate about the most appropriate clinical endpoint that should be used in future randomized controlled clinical trials of novel therapies in idiopathic pulmonary fibrosis. In a recent Pulmonary Perspective in this journal, the case for the use of a variety of clinical endpoints was analyzed, and the article concluded that FVC, the endpoint most commonly used recently and in ongoing studies, was not an appropriate option. In this Pulmonary Perspective we present a counterpoint in which we explore the basis on which this conclusion is drawn and present data that strongly and logically support the use of FVC as a valid and robust measure that fulfils the criteria for an ideal clinical endpoint and that is meaningful to patient and clinician alike.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citationA Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Cited by
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.02.001 · Cited by 463
Self-citationInterstitial lung disease in connective tissue disorders
Fischer, A., & du Bois, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61079-4 · Cited by 430
Self-citationImpact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Petnak, T., Lertjitbanjong, P., Thongprayoon, C., & Moua, T. (2021) · Chest · doi:10.1016/j.chest.2021.06.049 · Cited by 220
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
“This endpoint is judged to be both clinically meaningful and important to patients (17).”
BackgroundIdiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Metadata
- Authors
- du Bois, R. M., Nathan, S. D., Richeldi, L., Schwarz, M. I., & Noble, P. W.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-10-15
- Volume
- 186
- Issue
- 8
- Pages
- 712-715
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2003201331
- Cited by
- 95
- References
- 3
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials. https://app.cochat.ai/papers/10.1164/rccm.201206-1010pp
- The paper
- du Bois, R. M., Nathan, S. D., Richeldi, L., Schwarz, M. I., & Noble, P. W. (2012). Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201206-1010pp
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.